|
G |
ACHE |
acetylcholinesterase (Yt blood group) |
multiple interactions |
EXP ISO |
Ranitidine binds to and results in decreased activity of ACHE protein; Ranitidine inhibits the reaction [Paraoxon results in decreased activity of ACHE protein] Ranitidine affects the reaction [Paraoxon results in decreased activity of ACHE protein] |
CTD |
PMID:15669026 PMID:15669039 PMID:16193528 |
|
NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
|
|
G |
ACKR3 |
atypical chemokine receptor 3 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ACKR3 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ACKR3 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ACKR3 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr 2:236,537,122...236,582,354
Ensembl chr 2:236,567,787...236,582,354
|
|
G |
ADAMTS1 |
ADAM metallopeptidase with thrombospondin type 1 motif 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ADAMTS1 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ADAMTS1 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ADAMTS1 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr21:26,835,755...26,845,409
Ensembl chr21:26,835,755...26,845,409
|
|
G |
ALB |
albumin |
multiple interactions |
ISO |
[Ranitidine co-treated with Diclofenac] results in decreased expression of ALB protein; Quercetin inhibits the reaction [[Ranitidine co-treated with Diclofenac] results in decreased expression of ALB protein] |
CTD |
PMID:28400101 |
|
NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
|
|
G |
ALDOA |
aldolase, fructose-bisphosphate A |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ALDOA mRNA |
CTD |
PMID:16415329 |
|
NCBI chr16:30,064,279...30,070,420
Ensembl chr16:30,064,164...30,070,457
|
|
G |
AMOTL2 |
angiomotin like 2 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Lipopolysaccharides results in increased expression of AMOTL2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 3:134,355,345...134,375,417
Ensembl chr 3:134,355,347...134,375,479
|
|
G |
ARHGEF11 |
Rho guanine nucleotide exchange factor 11 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ARHGEF11 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 1:156,934,840...157,046,903
Ensembl chr 1:156,934,840...157,046,903
|
|
G |
ATF3 |
activating transcription factor 3 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ATF3 mRNA; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ATF3 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr 1:212,565,407...212,620,777
Ensembl chr 1:212,565,334...212,620,777
|
|
G |
ATP1B1 |
ATPase Na+/K+ transporting subunit beta 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ATP1B1 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ATP1B1 mRNA]; Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of ATP1B1 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr 1:169,106,690...169,132,719
Ensembl chr 1:169,105,697...169,310,992
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP ISO |
Ranitidine inhibits the reaction [Rotenone results in increased expression of BAX protein] Ranitidine inhibits the reaction [Aspirin results in increased expression of BAX protein] |
CTD |
PMID:19723537 PMID:30885738 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCHE |
butyrylcholinesterase |
multiple interactions |
EXP |
Ranitidine binds to and results in decreased activity of BCHE protein; Ranitidine inhibits the reaction [Paraoxon results in decreased activity of BCHE protein] |
CTD |
PMID:15669026 PMID:16193528 |
|
NCBI chr 3:165,772,904...165,837,423
Ensembl chr 3:165,772,904...165,837,462
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Rotenone results in decreased expression of BCL2 protein] |
CTD |
PMID:19723537 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BHLHE40 |
basic helix-loop-helix family member e40 |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of BHLHE40 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 3:4,979,437...4,985,323
Ensembl chr 3:4,979,437...4,985,323
|
|
G |
BMP2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of BMP2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr20:6,767,686...6,780,246
Ensembl chr20:6,767,686...6,780,246
|
|
G |
BNIP3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of BNIP3 mRNA |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr10:131,967,684...131,981,923
Ensembl chr10:131,967,684...131,981,967
|
|
G |
BTG2 |
BTG anti-proliferation factor 2 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of BTG2 mRNA; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of BTG2 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr 1:203,305,519...203,309,602
Ensembl chr 1:203,305,491...203,309,602
|
|
G |
CALCA |
calcitonin related polypeptide alpha |
increases expression |
EXP |
Ranitidine results in increased expression of CALCA protein |
CTD |
PMID:12495560 |
|
NCBI chr11:14,966,668...14,972,351
Ensembl chr11:14,966,622...14,972,354
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP ISO |
Ranitidine inhibits the reaction [Rotenone results in increased cleavage of and results in increased activity of CASP3 protein] Ranitidine inhibits the reaction [Aspirin results in increased expression of CASP3 mRNA]; Ranitidine inhibits the reaction [Aspirin results in increased expression of CASP3 protein]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of CASP3 mRNA]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of CASP3 protein] |
CTD |
PMID:19723537 PMID:28648817 PMID:29523851 PMID:30580614 PMID:30885738 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Rotenone results in increased cleavage of CASP9 protein] |
CTD |
PMID:19723537 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Indomethacin results in decreased activity of CAT protein]; Ranitidine inhibits the reaction [Indomethacin results in increased activity of CAT protein] |
CTD |
PMID:16169175 PMID:16397915 PMID:17895592 PMID:18087811 PMID:18726076 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCNL1 |
cyclin L1 |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CCNL1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 3:157,143,121...157,160,147
Ensembl chr 3:157,146,508...157,160,760
|
|
G |
CD80 |
CD80 molecule |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein]] |
CTD |
PMID:12538815 |
|
NCBI chr 3:119,524,293...119,559,614
Ensembl chr 3:119,524,293...119,559,614
|
|
G |
CDK6 |
cyclin dependent kinase 6 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of CDK6 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 7:92,604,921...92,836,573
Ensembl chr 7:92,604,921...92,836,573
|
|
G |
CREM |
cAMP responsive element modulator |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CREM mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr10:35,126,846...35,212,958
Ensembl chr10:35,126,791...35,212,958
|
|
G |
CSF3 |
colony stimulating factor 3 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CSF3 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CSF3 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr17:40,015,440...40,017,813
Ensembl chr17:40,015,361...40,017,813
|
|
G |
CTSL |
cathepsin L |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CTSL mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 9:87,726,119...87,731,469
Ensembl chr 9:87,724,051...87,731,469
|
|
G |
CXCL1 |
C-X-C motif chemokine ligand 1 |
decreases expression |
ISO |
Ranitidine results in decreased expression of CXCL1 protein |
CTD |
PMID:12023551 |
|
NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308
|
|
G |
CXCL2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CXCL2 mRNA; [Ranitidine co-treated with Lipopolysaccharides] results in increased expression of CXCL2 protein; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CXCL2 mRNA]; Heparin inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CXCL2 protein]]; Pentoxifylline inhibits the reaction [[Ranitidine co-treated with Lipopolysaccharides] results in increased expression of CXCL2 protein]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CXCL2 protein] |
CTD |
PMID:16401727 PMID:16415329 PMID:17698507 |
|
NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196
|
|
G |
DDAH1 |
dimethylarginine dimethylaminohydrolase 1 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Indomethacin results in decreased expression of DDAH1 mRNA] |
CTD |
PMID:29523851 |
|
NCBI chr 1:85,318,485...85,578,200
Ensembl chr 1:85,318,481...85,578,363
|
|
G |
DDIT4 |
DNA damage inducible transcript 4 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of DDIT4 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr10:72,273,924...72,276,036
Ensembl chr10:72,273,919...72,276,036
|
|
G |
DIO3 |
iodothyronine deiodinase 3 |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of DIO3 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr14:101,561,495...101,563,452
Ensembl chr14:101,560,139...101,563,452
|
|
G |
DUSP1 |
dual specificity phosphatase 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of DUSP1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 5:172,768,096...172,771,195
Ensembl chr 5:172,768,096...172,771,195
|
|
G |
EFNA1 |
ephrin A1 |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of EFNA1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 1:155,127,876...155,134,899
Ensembl chr 1:155,127,876...155,134,899
|
|
G |
EGFL7 |
EGF like domain multiple 7 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of EGFL7 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 9:136,658,856...136,672,678
Ensembl chr 9:136,658,856...136,672,678
|
|
G |
EGFR |
epidermal growth factor receptor |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Indomethacin results in increased expression of EGFR mRNA] |
CTD |
PMID:29523851 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
EGLN3 |
egl-9 family hypoxia inducible factor 3 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of EGLN3 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of EGLN3 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr14:33,924,227...33,951,074
Ensembl chr14:33,924,227...34,462,774
|
|
G |
EGR1 |
early growth response 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of EGR1 mRNA; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of EGR1 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of F3 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
|
|
G |
FGF23 |
fibroblast growth factor 23 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of FGF23 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr12:4,368,227...4,379,712
Ensembl chr12:4,368,227...4,379,712
|
|
G |
FMO3 |
flavin containing dimethylaniline monoxygenase 3 |
affects metabolic processing |
EXP |
FMO3 protein affects the metabolism of Ranitidine |
CTD |
PMID:15286053 |
|
NCBI chr 1:171,090,905...171,117,819
Ensembl chr 1:171,090,901...171,117,819
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of FOS mRNA |
CTD |
PMID:16415329 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
|
|
G |
FOSL2 |
FOS like 2, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of FOSL2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 2:28,392,858...28,417,317
Ensembl chr 2:28,392,448...28,417,317
|
|
G |
FOXQ1 |
forkhead box Q1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of FOXQ1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 6:1,312,098...1,314,758
Ensembl chr 6:1,312,098...1,314,758
|
|
G |
FST |
follistatin |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of FST mRNA; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of FST mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 5:53,480,629...53,487,134
Ensembl chr 5:53,480,626...53,487,134
|
|
G |
GADD45A |
growth arrest and DNA damage inducible alpha |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GADD45A mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 1:67,685,201...67,688,334
Ensembl chr 1:67,685,201...67,688,334
|
|
G |
GAST |
gastrin |
affects expression multiple interactions |
EXP ISO |
Ranitidine affects the expression of GAST protein Ranitidine inhibits the reaction [GAST protein modified form results in increased secretion of Acids] |
CTD |
PMID:2470453 PMID:12503773 |
|
NCBI chr17:41,712,331...41,715,969
Ensembl chr17:41,712,331...41,715,969
|
|
G |
GOT1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GOT1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr10:99,396,870...99,430,624
Ensembl chr10:99,396,870...99,430,624
|
|
G |
GZMB |
granzyme B |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GZMB mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GZMB mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr14:24,630,954...24,634,190
Ensembl chr14:24,630,954...24,634,267
|
|
G |
H2AC25 |
H2A clustered histone 25 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of H2A mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 1:228,457,364...228,457,873
Ensembl chr 1:228,434,777...228,457,873
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Indomethacin results in decreased expression of HMOX1 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA] |
CTD |
PMID:16415329 PMID:30580614 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HNF4A |
hepatocyte nuclear factor 4 alpha |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of HNF4A mRNA |
CTD |
PMID:16415329 |
|
NCBI chr20:44,355,699...44,434,596
Ensembl chr20:44,355,699...44,432,845
|
|
G |
HOMER1 |
homer scaffold protein 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of HOMER1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 5:79,372,636...79,514,134
Ensembl chr 5:79,372,636...79,514,134
|
|
G |
HOXA5 |
homeobox A5 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of HOXA5 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 7:27,141,052...27,143,681
Ensembl chr 7:27,141,052...27,143,681
|
|
G |
HRH2 |
histamine receptor H2 |
multiple interactions decreases activity |
EXP ISO |
[Ranitidine binds to and results in decreased activity of HRH2 protein] which affects the susceptibility to Metformin; Ranitidine binds to and results in decreased activity of HRH2 protein; Ranitidine inhibits the reaction [tiotidine binds to HRH2 protein] Ranitidine results in decreased activity of HRH2 protein Ranitidine binds to and results in decreased activity of HRH2 protein; Ranitidine inhibits the reaction [Dimaprit binds to and results in increased activity of HRH2 protein]; Ranitidine inhibits the reaction [Melitten results in increased activity of HRH2 protein] |
CTD |
PMID:6106871 PMID:6835285 PMID:7512805 PMID:9681472 PMID:9819373 PMID:11527950 PMID:12100006 PMID:14671421 PMID:16143415 PMID:16632449 PMID:22995146 More...
|
|
NCBI chr 5:175,658,071...175,710,756
Ensembl chr 5:175,658,030...175,710,756
|
|
G |
HSPA1A |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of HSPA1A mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 6:31,815,543...31,817,942
Ensembl chr 6:31,815,543...31,817,946
|
|
G |
HSPB8 |
heat shock protein family B (small) member 8 |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of HSPB8 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855
|
|
G |
ICAM1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of ICAM1 protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]] |
CTD |
PMID:11752121 PMID:12538815 |
|
NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
|
|
G |
ID2 |
inhibitor of DNA binding 2 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of ID2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 2:8,682,056...8,684,461
Ensembl chr 2:8,678,845...8,684,461
|
|
G |
ID4 |
inhibitor of DNA binding 4 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of ID4 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 6:19,837,370...19,842,197
Ensembl chr 6:19,837,370...19,842,197
|
|
G |
IFNG |
interferon gamma |
multiple interactions |
EXP ISO |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of IFNG protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG protein]] [IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Ranitidine; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IFNG mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IFNG protein] |
CTD |
PMID:10569698 PMID:11752121 PMID:16415329 PMID:17698507 PMID:19362101 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IFRD1 |
interferon related developmental regulator 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IFRD1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 7:112,423,174...112,477,203
Ensembl chr 7:112,422,887...112,481,017
|
|
G |
IGSF10 |
immunoglobulin superfamily member 10 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IGSF10 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IGSF10 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr 3:151,432,432...151,619,925
Ensembl chr 3:151,425,384...151,461,061
|
|
G |
IL10 |
interleukin 10 |
multiple interactions |
ISO EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IL10 protein] Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in decreased expression of IL10 protein]] |
CTD |
PMID:11752121 PMID:17698507 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL12A |
interleukin 12A |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]]; Ranitidine inhibits the reaction [Histamine results in decreased expression of IL12A protein] |
CTD |
PMID:9819373 PMID:11752121 |
|
NCBI chr 3:159,988,835...159,996,019
Ensembl chr 3:159,988,835...159,996,019
|
|
G |
IL12B |
interleukin 12B |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]]; Ranitidine inhibits the reaction [Histamine results in decreased expression of IL12B protein] |
CTD |
PMID:9819373 PMID:11752121 |
|
NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,863
|
|
G |
IL18 |
interleukin 18 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Cimetidine results in increased expression of IL18 protein]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in decreased expression of IL10 protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of ICAM1 protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of IFNG protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of TNF protein]] |
CTD |
PMID:11752121 PMID:16723495 |
|
NCBI chr11:112,143,260...112,164,094
Ensembl chr11:112,143,253...112,164,096
|
|
G |
IL1A |
interleukin 1 alpha |
multiple interactions |
ISO |
[IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Ranitidine |
CTD |
PMID:19362101 |
|
NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493
|
|
G |
IL1B |
interleukin 1 beta |
increases expression multiple interactions |
ISO |
Ranitidine results in increased expression of IL1B protein Pentoxifylline inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; Ranitidine inhibits the reaction [Capsaicin results in increased expression of IL1B protein]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of IL1B mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:15265675 PMID:17698507 PMID:30580614 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL4 |
interleukin 4 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Indomethacin results in increased expression of IL4 protein] |
CTD |
PMID:29523851 |
|
NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IL6 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IL6 mRNA]; Pentoxifylline inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; Ranitidine inhibits the reaction [Capsaicin results in increased expression of IL6 protein]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of IL6 protein]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein] |
CTD |
PMID:15265675 PMID:16401727 PMID:16415329 PMID:17698507 PMID:28648817 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
INHBE |
inhibin subunit beta E |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of INHBE mRNA |
CTD |
PMID:16415329 |
|
NCBI chr12:57,455,307...57,458,025
Ensembl chr12:57,452,323...57,459,280
|
|
G |
INSIG1 |
insulin induced gene 1 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of INSIG1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 7:155,297,878...155,310,235
Ensembl chr 7:155,297,776...155,310,235
|
|
G |
INSIG2 |
insulin induced gene 2 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of INSIG2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 2:118,088,471...118,110,997
Ensembl chr 2:118,088,452...118,110,997
|
|
G |
IRS2 |
insulin receptor substrate 2 |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IRS2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr13:109,752,695...109,786,583
Ensembl chr13:109,752,695...109,786,583
|
|
G |
ITPKC |
inositol-trisphosphate 3-kinase C |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ITPKC mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr19:40,717,112...40,740,860
Ensembl chr19:40,717,112...40,740,860
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of JUN mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
|
|
G |
KLF4 |
KLF transcription factor 4 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of KLF4 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of KLF4 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr 9:107,484,852...107,489,769
Ensembl chr 9:107,484,852...107,490,482
|
|
G |
KLF6 |
KLF transcription factor 6 |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of KLF6 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr10:3,775,996...3,785,209
Ensembl chr10:3,775,996...3,785,281
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Rotenone results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19723537 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Rotenone results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19723537 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPKAPK2 |
MAPK activated protein kinase 2 |
multiple interactions increases expression |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of MAPKAPK2 mRNA Ranitidine results in increased expression of MAPKAPK2 mRNA |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr 1:206,684,905...206,734,281
Ensembl chr 1:206,684,905...206,734,281
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Ethanol results in increased secretion of and results in increased activity of MMP9 protein]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of MMP9 protein] |
CTD |
PMID:17603938 PMID:29523851 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
MPO |
myeloperoxidase |
multiple interactions decreases expression |
ISO |
Ranitidine inhibits the reaction [Aspirin results in increased expression of MPO protein]; Ranitidine inhibits the reaction [Indomethacin results in increased activity of MPO protein] Ranitidine results in decreased expression of MPO protein |
CTD |
PMID:12023551 PMID:16169175 PMID:17895592 PMID:18726076 PMID:28648817 PMID:30885738 More...
|
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of MYC mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
NEDD4L |
NEDD4 like E3 ubiquitin protein ligase |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of NEDD4L mRNA |
CTD |
PMID:16415329 |
|
NCBI chr18:58,044,226...58,401,540
Ensembl chr18:58,044,226...58,401,540
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Indomethacin results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:28648817 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NGF |
nerve growth factor |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Capsaicin results in increased expression of NGF protein] |
CTD |
PMID:15265675 |
|
NCBI chr 1:115,285,917...115,338,249
Ensembl chr 1:115,285,904...115,338,770
|
|
G |
NOCT |
nocturnin |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of NOCT mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 4:139,015,781...139,045,939
Ensembl chr 4:139,015,781...139,045,939
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Indomethacin results in increased activity of NOS2 protein] |
CTD |
PMID:16169175 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Indomethacin results in decreased expression of NQO1 protein] |
CTD |
PMID:30580614 |
|
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
NR4A1 |
nuclear receptor subfamily 4 group A member 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of NR4A1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr12:52,022,832...52,059,503
Ensembl chr12:52,022,832...52,059,507
|
|
G |
NUPR1 |
nuclear protein 1, transcriptional regulator |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of NUPR1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr16:28,532,708...28,538,974
Ensembl chr16:28,532,708...28,539,008
|
|
G |
P4HA1 |
prolyl 4-hydroxylase subunit alpha 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of P4HA1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr10:73,007,217...73,096,866
Ensembl chr10:73,007,217...73,096,974
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein] |
CTD |
PMID:19723537 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PFKL |
phosphofructokinase, liver type |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of PFKL mRNA |
CTD |
PMID:16415329 |
|
NCBI chr21:44,300,053...44,327,373
Ensembl chr21:44,300,051...44,327,376
|
|
G |
PPP1R15A |
protein phosphatase 1 regulatory subunit 15A |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of PPP1R15A mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr19:48,872,421...48,876,058
Ensembl chr19:48,872,212...48,876,059
|
|
G |
PREB |
prolactin regulatory element binding |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Lipopolysaccharides results in increased expression of PREB mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 2:27,130,756...27,134,636
Ensembl chr 2:27,130,756...27,134,666
|
|
G |
PRL |
prolactin |
affects expression increases secretion |
EXP |
Ranitidine affects the expression of PRL protein Ranitidine results in increased secretion of PRL protein |
CTD |
PMID:7878608 PMID:9037573 |
|
NCBI chr 6:22,287,246...22,302,835
Ensembl chr 6:22,287,244...22,302,826
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of PTGS2 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of PTGS2 mRNA]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of PTGS2 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16401727 PMID:16415329 PMID:29523851 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
PVR |
PVR cell adhesion molecule |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of PVR mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr19:44,643,910...44,666,162
Ensembl chr19:44,643,798...44,666,162
|
|
G |
RAC1 |
Rac family small GTPase 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of RAC1 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of RAC1 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr 7:6,374,527...6,403,967
Ensembl chr 7:6,374,527...6,403,967
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Indomethacin results in increased expression of RELA mRNA]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of RELA protein] |
CTD |
PMID:28648817 PMID:30580614 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
REN |
renin |
affects activity |
EXP |
Ranitidine affects the activity of REN protein |
CTD |
PMID:1972605 |
|
NCBI chr 1:204,154,819...204,166,337
Ensembl chr 1:204,154,819...204,190,324
|
|
G |
RGS2 |
regulator of G protein signaling 2 |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of RGS2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 1:192,809,039...192,812,275
Ensembl chr 1:192,809,039...192,812,275
|
|
G |
RGS4 |
regulator of G protein signaling 4 |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of RGS4 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 1:163,068,871...163,076,802
Ensembl chr 1:163,068,775...163,076,802
|
|
G |
RHOB |
ras homolog family member B |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ARHB mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 2:20,447,074...20,449,440
Ensembl chr 2:20,447,074...20,449,440
|
|
G |
SERPINE1 |
serpin family E member 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SERPINE1 mRNA; Heparin inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein]]; Pentoxifylline inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein]]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein] |
CTD |
PMID:16401727 PMID:16415329 PMID:17698507 |
|
NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
|
|
G |
SH2B2 |
SH2B adaptor protein 2 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of APS mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 7:102,285,141...102,321,711
Ensembl chr 7:102,285,091...102,321,711
|
|
G |
SHANK3 |
SH3 and multiple ankyrin repeat domains 3 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of SHANK3 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr22:50,672,823...50,733,212
Ensembl chr22:50,674,408...50,733,212
|
|
G |
SIK1 |
salt inducible kinase 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SIK1 mRNA; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SIK1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr21:43,414,483...43,427,131
Ensembl chr21:43,414,483...43,427,131
|
|
G |
SLC16A6 |
solute carrier family 16 member 6 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLC16A6 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr17:68,267,026...68,291,479
Ensembl chr17:68,267,026...68,291,267
|
|
G |
SLC20A1 |
solute carrier family 20 member 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLC20A1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 2:112,645,939...112,663,825
Ensembl chr 2:112,645,939...112,663,825
|
|
G |
SLC22A1 |
solute carrier family 22 member 1 |
multiple interactions affects transport increases uptake |
EXP ISO |
Ranitidine inhibits the reaction [SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Ranitidine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] SLC22A1 protein affects the transport of Ranitidine SLC22A1 protein results in increased uptake of Ranitidine |
CTD |
PMID:16006492 PMID:16141367 PMID:16263091 |
|
NCBI chr 6:160,121,815...160,158,718
Ensembl chr 6:160,121,815...160,158,718
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
increases uptake multiple interactions |
EXP ISO |
SLC22A2 protein results in increased uptake of Ranitidine Ranitidine inhibits the reaction [SLC22A2 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Ranitidine inhibits the reaction [SLC22A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16006492 PMID:16141367 PMID:16263091 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
G |
SLC22A3 |
solute carrier family 22 member 3 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [SLC22A3 protein affects the transport of 1-Methyl-4-phenylpyridinium]; Ranitidine inhibits the reaction [SLC22A3 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Ranitidine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16141367 PMID:16263091 |
|
NCBI chr 6:160,348,378...160,452,577
Ensembl chr 6:160,348,378...160,452,577
|
|
G |
SLC22A6 |
solute carrier family 22 member 6 |
increases uptake |
EXP |
SLC22A6 protein results in increased uptake of Ranitidine |
CTD |
PMID:16006492 |
|
NCBI chr11:62,976,597...62,984,967
Ensembl chr11:62,936,385...62,984,967
|
|
G |
SLC22A7 |
solute carrier family 22 member 7 |
increases uptake |
EXP |
SLC22A7 protein results in increased uptake of Ranitidine |
CTD |
PMID:16006492 |
|
NCBI chr 6:43,295,714...43,305,538
Ensembl chr 6:43,295,694...43,305,538
|
|
G |
SLC22A8 |
solute carrier family 22 member 8 |
increases uptake multiple interactions |
EXP ISO |
SLC22A8 protein results in increased uptake of Ranitidine Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of Ranitidine]; Probenecid promotes the reaction [SLC22A8 protein results in increased uptake of Ranitidine]; Ranitidine inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine] |
CTD |
PMID:15319347 PMID:16006492 |
|
NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841
|
|
G |
SLC2A1 |
solute carrier family 2 member 1 |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SLC2A1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 1:42,925,353...42,958,868
Ensembl chr 1:42,925,353...42,958,893
|
|
G |
SLC38A2 |
solute carrier family 38 member 2 |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SLC38A2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr12:46,358,188...46,372,773
Ensembl chr12:46,358,188...46,372,773
|
|
G |
SLC47A1 |
solute carrier family 47 member 1 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr17:19,533,854...19,579,034
Ensembl chr17:19,495,385...19,579,034
|
|
G |
SLC47A2 |
solute carrier family 47 member 2 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr17:19,678,317...19,718,979
Ensembl chr17:19,678,288...19,718,979
|
|
G |
SLC5A3 |
solute carrier family 5 member 3 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLC5A3 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLC5A3 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr21:34,073,578...34,106,260
Ensembl chr21:34,073,578...34,106,260
|
|
G |
SLK |
STE20 like kinase |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLK mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLK mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr10:103,967,140...104,029,233
Ensembl chr10:103,967,140...104,029,233
|
|
G |
SPHK1 |
sphingosine kinase 1 |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SPHK1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr17:76,383,204...76,387,855
Ensembl chr17:76,376,584...76,387,860
|
|
G |
TAC1 |
tachykinin precursor 1 |
increases expression |
EXP |
Ranitidine results in increased expression of TAC1 protein |
CTD |
PMID:12495560 |
|
NCBI chr 7:97,732,086...97,740,472
Ensembl chr 7:97,732,084...97,740,472
|
|
G |
TFRC |
transferrin receptor |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of TFRC mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of TFRC mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr 3:196,049,284...196,082,090
Ensembl chr 3:196,012,511...196,082,153
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP ISO |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of TNF protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]] [IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Ranitidine; Ranitidine inhibits the reaction [Aspirin results in increased expression of TNF protein]; Ranitidine inhibits the reaction [Capsaicin results in increased expression of TNF protein]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of TNF protein]; Ranitidine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:11752121 PMID:12023551 PMID:12538815 PMID:15265675 PMID:17698507 PMID:19362101 PMID:28648817 PMID:29523851 PMID:30885738 More...
|
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFAIP6 |
TNF alpha induced protein 6 |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of TNFAIP6 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 2:151,357,592...151,381,340
Ensembl chr 2:151,357,592...151,380,046
|
|
G |
TNFRSF12A |
TNF receptor superfamily member 12A |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of TNFRSF12A mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr16:3,020,368...3,022,383
Ensembl chr16:3,018,445...3,022,383
|
|
G |
TPM3 |
tropomyosin 3 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of TPM3 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 1:154,155,308...154,192,100
Ensembl chr 1:154,155,308...154,194,648
|
|
G |
TRAK2 |
trafficking kinesin protein 2 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of TRAK2 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 2:201,377,207...201,451,458
Ensembl chr 2:201,377,207...201,451,500
|
|
G |
UBE2B |
ubiquitin conjugating enzyme E2 B |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of UBE2B mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 5:134,371,569...134,392,108
Ensembl chr 5:134,371,184...134,392,108
|
|
G |
VEGFA |
vascular endothelial growth factor A |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of VEGFA mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
G |
ZBTB10 |
zinc finger and BTB domain containing 10 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ZBTB10 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 8:80,485,593...80,526,265
Ensembl chr 8:80,485,619...80,526,265
|
|
G |
ZFYVE27 |
zinc finger FYVE-type containing 27 |
multiple interactions |
ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ZFYVE27 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr10:97,737,128...97,760,895
Ensembl chr10:97,737,121...97,760,907
|
|